Woodcock Janet, Witter James, Dionne Raymond A
Food and Drug Administration, Department of Health and Human Services, Rockville, Maryland, USA.
Nat Rev Drug Discov. 2007 Sep;6(9):703-10. doi: 10.1038/nrd2335.
Biomedical science has greatly improved our understanding of pain in recent decades, but few novel molecular entities that address fundamentally new pain mechanisms have entered the clinic, despite dramatically increased pharmaceutical investment. Indeed, virtually all new analgesics approved over the past 25 years are derivatives or reformulations of opioids or aspirin-like drugs, existing drugs given for a new indication or older drugs given by a different route of administration. Here, we discuss factors contributing to this lack of innovation in therapies for pain and advocate public-private partnerships (PPPs) to translate new knowledge into more efficacious and safer treatments.
近几十年来，生物医学科学极大地增进了我们对疼痛的理解。然而，尽管制药投资大幅增加，但很少有针对全新疼痛机制的新型分子实体进入临床应用。事实上，过去25年里获批的几乎所有新型镇痛药都是阿片类药物或阿司匹林样药物的衍生物或重新配方，即现有药物用于新的适应症，或老药采用不同给药途径。在此，我们讨论导致疼痛治疗缺乏创新的因素，并倡导公私合作伙伴关系（PPPs），以将新知识转化为更有效、更安全的治疗方法。
